CoChat

JAK1/3 inhibition preserves epidermal morphology in full‐thickness 3D skin models of atopic dermatitis and psoriasis

Open access
Clarysse, K., Pfaff, C.M., Marquardt, Y., Huth, L., Kortekaas Krohn, I., Kluwig, D., Lüscher, B., Gutermuth, J., Baron, J. · 2019 · Journal of the European Academy of Dermatology and Venereology
Cited by 64

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Background: Janus kinase (JAK) inhibition may be a promising new treatment modality for inflammatory (skin) diseases. However, little is known about direct effects of kinase inhibitors on keratinocyte differentiation and function as well as skin barrier formation. Objective: Our aim was to address the direct impact of kinase inhibition of the JAK1/3 pathways by tofacitinib on keratinocyte immune function and barrier formation in atopic dermatitis (AD) and psoriasis. Methods: 3D skin equivalents of both diseases were developed and concurrently pretreated with tofacitinib. To induce AD, 3D skin equivalents were stimulated with recombinant human IL‐4 and IL‐13. Psoriasis‐like conditions were induced by incubation with IL‐17A, IL‐22 and tumour necrosis factor α (TNFα). The activation of signal transducer and activator of transcription (STAT)1, STAT3 and STAT6 was assessed by Western blot analysis. Microarray analysis and quantitative real‐time PCR were used for gene expression analysis. Results: Tofacitinib pretreatment preserved epidermal morphology and reduced STAT3 and STAT6 phosphorylation of AD‐like and STAT3 phosphorylation of psoriasis‐like culture conditions in 3D skin models compared to sham‐controls. Filaggrin expression was fully maintained in the AD‐like models, but only partially in psoriasis‐like conditions after pretreatment with tofacitinib. In addition, tofacitinib upregulated DSC1, FLG and KRT1. Using gene expression analysis, downregulation of POSTN and IL24 was observed in AD‐like conditions, whereas downregulation of IL20 and IL1B was observed in psoriasis‐like conditions. Conclusion: JAK1/3 inhibition counteracted cytokine‐induced AD‐ and psoriasis‐like epidermal morphology and enhanced keratinocyte differentiation in 3D skin models. This effect was more pronounced in the AD‐like models compared to the psoriasis‐like 3D skin models.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jdv.15301

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 64

Metadata

Authors
Clarysse, K., Pfaff, C. M., Marquardt, Y., Huth, L., Kortekaas Krohn, I., Kluwig, D., Lüscher, B., Gutermuth, J., & Baron, J.
Venue
Journal of the European Academy of Dermatology and Venereology
Publisher
Wiley
Published
2019-01
Volume
33
Issue
2
Pages
367-375
ISSN
  • 0926-9959 (ISSN-L)
  • 1468-3083
OpenAlex
W2898471473
Cited by
64
References
4
FWCI
6.24
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: JAK1/3 inhibition preserves epidermal morphology in full‐thickness 3D skin models of atopic dermatitis and psoriasis. https://app.cochat.ai/papers/10.1111/jdv.15301
The paper
Clarysse, K., Pfaff, C. M., Marquardt, Y., Huth, L., Kortekaas Krohn, I., Kluwig, D., Lüscher, B., Gutermuth, J., & Baron, J. (2019). JAK1/3 inhibition preserves epidermal morphology in full‐thickness 3D skin models of atopic dermatitis and psoriasis. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.15301

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.